carboxyamido-triazole has been researched along with Gastrointestinal Stromal Neoplasm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ | 1 |
1 other study(ies) available for carboxyamido-triazole and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult | 2010 |